STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF ELAMIPRETIDE NDA RESUBMISSION

NEEDHAM, Mass., Aug. 21, 2025 /PRNewswire/ -- Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that the U.S. Food and Drug...